"Strong Growth Estimated for Q1 Sales and Operating Profit"
Momentum in Exports of Body Composition Analyzers and Home Consumer Segment

Sangsangin Securities on April 8 maintained its "Buy" investment rating and a target price of 43,000 won for InBody, citing a positive earnings outlook for the first half of the year.


On this day, Sangsangin Securities researcher Ha Taegi assessed, "InBody is a competitive company that is building its original brand in the global export market and achieving stable growth."


The first point of note is the upcoming earnings season for the first half of this year. Researcher Ha estimated, "InBody's consolidated sales for the first quarter of this year are expected to reach 65.4 billion won, up 17.7% year-on-year, with operating profit surging 51.4% to 10.6 billion won." He explained, "In addition to sales growth, the burden of selling and administrative expenses, which was concentrated last year, is expected to ease, resulting in a significant increase in operating profit."

[Click eStock] "InBody Begins Full-Fledged Overseas High Growth and Profitability Improvement" View original image

The export segment is also a strong growth driver. Exports of body composition analyzers, which account for about 70% of total sales, are projected to grow 20% year-on-year to 43.2 billion won, driven by increased volumes in North America and Europe. The consumer segment, which includes home-use body composition analyzers, is also estimated to post first-quarter sales of 8.1 billion won, up 23.6% from a year earlier, benefiting from organizational restructuring.


Researcher Ha noted, "Last year, operating profit stagnated due to increased selling and administrative expenses stemming from the expansion of overseas subsidiaries and branches, but most of the major spending has now been completed." He added, "From this year, improvement in the cost ratio thanks to export growth and a decrease in the SG&A ratio will lead to a higher operating margin."



Strengthening the shareholder return policy is also positive. InBody has recently set a target payout ratio of about 25% of consolidated net profit and raised its dividend per share from 400 won to 600 won. Researcher Ha said, "The current share price is at a price-to-earnings ratio (PER) of 8 to 9 times based on this year's and next year's earnings. Considering that InBody is a stable growth stock less affected by economic cycles, the current share price is significantly undervalued relative to its fundamentals."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing